Lv7
5008 积分 2021-12-16 加入
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
25天前
已完结
Design, synthesis and evaluation of novel 1,3-benzodioxole derivatives for their anti-tumor activity
25天前
已完结
Type 2 immunity: Expanding our view
1个月前
已完结
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
1个月前
已完结
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
1个月前
已完结
An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability
1个月前
已完结
A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity
1个月前
已完结
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
1个月前
已完结
Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade
1个月前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
